Interesting PR on a HER2/neu vaccine.
December 14, 2006 09:30 AM Eastern Time
HER2/neu Vaccine Results Spurs Phase III Planning by Apthera, Inc.
29th Annual San Antonio Breast Cancer Symposium
SCOTTSDALE, Ariz.--(BUSINESS WIRE)--Col. George E. Peoples, M.D., Chief of Surgical Oncology at Brooke Army Medical Center in San Antonio, TX will be presenting the results of a 200 patient Phase II study of a HER2/neu vaccine (E75) for the prevention of recurrence in high risk breast cancer patients at the 29th Annual San Antonio Breast Cancer Symposium, the premier breast cancer educational and scientific event. Dr. Peoples will present positive interim analysis of the Phase II study of E75 on Thursday, December 14th at 10:30am (CST) at the Georgia and Henry B. Gonzalez Convention Center in San Antonio, Texas.
Based on the advanced development stage of this product and the promising Phase I and Phase II results, Apthera, Inc. has exclusively licensed E75 from The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. and another major academic institution.
About the Company
Apthera, Inc. is a private company established in July, 2005 to develop and commercialize advanced-stage clinical programs in cancer immunotherapy licensed from renowned academic institutions. Apthera’s initial focus is on funding and completing the final phases of development of E75 (NeuVax™). Apthera’s licensed technology is based on the use of single immunostimulatory peptides, such as E75, and peptide combinations to activate multiple “killer” T-cell clones against multiple tumor antigen epitopes. This new adjunct therapy, used in a clinical setting of minimal residual disease, will result in less disease recurrence and improved long-term cancer survival. Apthera has patents and strong proprietary protection on the naturally-presented human leukocyte antigen (HLA) peptides, methods of use, compositions, modifications, and processes. NeuVax™ is being readied for Phase III studies and indicated for the adjuvant treatment of breast and prostate cancers, and other HER2/neu-expressing tumors. Based upon the early success achieved in the clinic, the company now plans an end-of-Phase II meeting with FDA to discuss a Special Protocol Assessment (SPA) and the design and conduct of a large, randomized, pivotal Phase III registration study for the breast cancer indication.
This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements are not historical facts and are subject to risks and uncertainties which could cause actual results and the timing of certain events to differ materially from those set forth in or implied herein including, without limitation, risks associated with clinical development, regulatory approvals, product commercialization, intellectual property claims litigation and other risks associated with the Company’s proposed activities.
